Multifunctional nanoagonist enhances photodynamic therapy-driven in situ cancer vaccination by inhibiting tumor thrombosis.

ABSTRACT: Converting autologous tumors into therapeutic cancer vaccines represents an attractive strategy for achieving personalized antitumor immunity. However, the antitumor immune response is significantly compromised by the tumor microenvironment (TME). Herein, we developed a polymersomal nanoagonist (cDVPMA) to potentiate photodynamic therapy (PDT)-driven in situ cancer vaccination (ISCV) by inhibiting intratumoral thrombosis. cDVPMA was constructed by encapsulating the stimulator of interferon genes (STING) agonist 2'3'-cGAMP in the aqueous core of a tertiary ammonium group-containing polymersome, while embedding both the photosensitizer verteporfin-phospholipid (VL) and thrombin inhibitor dabigatran etexilate within the hydrophobic layer. Upon tumor accumulation, cDVPMA swells in response to

SUBMITTER: Liu C 

PROVIDER: S-EPMC12632146 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature